NEWTON,
Mass., Oct. 1, 2024 /PRNewswire/ -- Karyopharm
Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical
company pioneering novel cancer therapies, today announced that the
Company granted an aggregate of 17,000 restricted stock units
(RSUs) to three newly-hired employees. These RSU awards were
granted as of September 30, 2024 (the
"Grant Date") pursuant to the Company's 2022 Inducement Stock
Incentive Plan, as amended, as inducements material to the new
employees entering into employment with Karyopharm in accordance
with Nasdaq Listing Rule 5635(c)(4).
Each RSU award will vest over three years, with 33 1/3% of the
shares underlying the RSU award vesting on each of the three
consecutive anniversaries of the Grant Date. The vesting of each
RSU award is subject to the employee's continued service as an
employee of, or other service provider to, Karyopharm through the
applicable vesting dates. In addition, each RSU award will be
immediately exercisable in full if, on or prior to the first
anniversary of the consummation of a "change in control event," the
employee's employment is terminated for "good reason" by the
employee or terminated without "cause" by Karyopharm (as such terms
are defined in the applicable RSU agreement).
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a
commercial-stage pharmaceutical company whose dedication to
pioneering novel cancer therapies is fueled by a belief in the
extraordinary strength and courage of patients with cancer. Since
its founding, Karyopharm has been an industry leader in
oral compounds that address nuclear export dysregulation, a
fundamental mechanism of oncogenesis. Karyopharm's lead
compound and firstinclass, oral exportin 1 (XPO1) inhibitor,
XPOVIO® (selinexor), is approved in the U.S.
and marketed by the Company in three oncology indications. It
has also received regulatory approvals in various indications in a
growing number of exU.S. territories and countries, including
Europe and the United Kingdom (as NEXPOVIO®) and
China. Karyopharm has
a focused pipeline targeting indications in multiple high
unmet need cancers, including in multiple myeloma, endometrial
cancer, myelofibrosis, and diffuse large
B-cell lymphoma (DLBCL).
For more information about our people,
science and pipeline, please visit
www.karyopharm.com, and follow us on LinkedIn and on X at
@Karyopharm.
XPOVIO® and NEXPOVIO® are registered
trademarks of Karyopharm Therapeutics Inc.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302263260.html
SOURCE Karyopharm Therapeutics Inc.
